BioPharma Resources

Drug Trial Radar · NCT07406360

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,209 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,209

Planned (sponsor's estimate)

Start

May 11, 2026

Primary completion

Feb 28, 2028

Study completion Jul 20, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 15 months, up to 6 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose in children 15 months to 6 years of age who were previously primed with a first dose of any combination of measles, mumps, rubella and varicella-containing vaccine(s).

Conditions

  • Measles
  • Measles-Mumps-Rubella+Chickenpox Vaccine

Interventions

  • MMRVNSBiological

    One dose of MMRVNS administered intramuscularly.

  • MMRVBiological

    One dose of MMRV administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroresponse of Immunoglobulin G (IgG) concentrations against measlesTime frame: At Day 43
  2. Seroresponse of IgG concentrations against mumpsTime frame: At Day 43
  3. Seroresponse of IgG concentrations against rubellaTime frame: At Day 43
  4. Seroresponse of IgG concentrations against Varicella zoster virus (VZV)Time frame: At Day 43
  5. IgG concentrations against measlesTime frame: At Day 43
  6. IgG concentrations against mumpsTime frame: At Day 43
  7. IgG concentrations against rubellaTime frame: At Day 43
  8. IgG concentrations against VZVTime frame: At Day 43

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama · Recruiting

  • GSK Investigational Site

    Walnut Creek, California · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Atlanta, Georgia · Recruiting

  • GSK Investigational Site

    Chicago, Illinois · Recruiting

  • GSK Investigational Site

    Farmington Hills, Michigan · Recruiting

  • GSK Investigational Site

    Dayton, Ohio · Recruiting

  • GSK Investigational Site

    Simpsonville, South Carolina · Recruiting

  • GSK Investigational Site

    Spartanburg, South Carolina · Recruiting

  • GSK Investigational Site

    Frisco, Texas · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Port Lavaca, Texas · Recruiting

  • GSK Investigational Site

    Richmond, Texas · Recruiting

  • GSK Investigational Site

    Provo, Utah · Recruiting

  • GSK Investigational Site

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.